FOXA2 is a Sensitive and Specific Marker for Small Cell Neuroendocrine Carcinoma of the Prostate

Overview

Journal Mod Pathol

Specialty Pathology

Date 2017 Jun 17

PMID 28621319

Citations 53

Authors

Jung Wook Park

John K Lee

Owen N Witte

Jiaoti Huang

Affiliations

Soon will be listed here.

Abstract

The median survival of patients with small cell neuroendocrine carcinoma is significantly shorter than that of patients with classic acinar-type adenocarcinoma. Small cell neuroendocrine carcinoma is traditionally diagnosed based on histologic features because expression of current immunohistochemical markers is inconsistent. This is a challenging diagnosis even for expert pathologists and particularly so for pathologists who do not specialize in prostate cancer. New biomarkers to aid in the diagnosis of small cell neuroendocrine carcinoma are therefore urgently needed. We discovered that FOXA2, a pioneer transcription factor, is frequently and specifically expressed in small cell neuroendocrine carcinoma compared with prostate adenocarcinoma from published mRNA-sequencing data of a wide range of human prostate cancers. We verified the expression of FOXA2 in human prostate cancer cell lines and xenografts, patient biopsy specimens, tissue microarrays of prostate cancers with lymph node metastasis, primary small cell neuroendocrine carcinoma, and metastatic treatment-related small cell neuroendocrine carcinoma and cases from a rapid autopsy program. FOXA2 expression was present in NCI-H660 and PC3 neuroendocrine cell lines, but not in LNCAP and CWR22 adenocarcinoma cell lines. Of the human prostate cancer specimens, 20 of 235 specimens (8.5%) showed diagnostic histologic features of small cell neuroendocrine carcinoma as judged histologically. Fifteen of 20 small cell neuroendocrine carcinoma tissues (75%) showed strong expression of FOXA2 (staining intensity 2 or 3). FOXA2 expression was also detected in 9 of 215 prostate cancer tissues (4.2%) that were histologically defined as adenocarcinoma. Our findings demonstrate that FOXA2 is a sensitive and specific molecular marker that may be extremely valuable in the pathologic diagnosis of small cell neuroendocrine carcinoma.

Citing Articles

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.

Maylin Z, Smith C, Classen A, Asim M, Pandha H, Wang Y Cells. 2024; 13(23).

PMID: 39682746 PMC: 11639977. DOI: 10.3390/cells13231999.

LBFextract: Unveiling transcription factor dynamics from liquid biopsy data.

Lazzeri I, Spiegl B, Hasenleithner S, Speicher M, Kircher M Comput Struct Biotechnol J. 2024; 23:3163-3174.

PMID: 39660220 PMC: 11630664. DOI: 10.1016/j.csbj.2024.08.007.

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer.

Nouruzi S, Namekawa T, Tabrizian N, Kobelev M, Sivak O, Scurll J JCI Insight. 2024; 9(23).

PMID: 39470735 PMC: 11623946. DOI: 10.1172/jci.insight.185952.

Development of 3D-iNET ORION: a novel, pre-clinical, three-dimensional in vitro cell model for modeling human metastatic neuroendocrine tumor of the pancreas.

Strnadel J, Valasek M, Lin G, Lin H, Tipps A, Woo S Hum Cell. 2024; 37(5):1593-1601.

PMID: 39103560 PMC: 11341600. DOI: 10.1007/s13577-024-01113-7.

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.

Wang Z, Townley S, Zhang S, Liu M, Li M, Labaf M Nat Commun. 2024; 15(1):4914.

PMID: 38851846 PMC: 11162502. DOI: 10.1038/s41467-024-49234-9.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Zhang X, Coleman I, Brown L, True L, Kollath L, Lucas J . SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015; 21(20):4698-708. PMC: 4609255. DOI: 10.1158/1078-0432.CCR-15-0157. View

Ather M, Abbas F, Faruqui N, Israr M, Pervez S . Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2009; 8:21. PMC: 2628675. DOI: 10.1186/1471-2490-8-21. View

Mirosevich J, Gao N, Matusik R . Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate. 2004; 62(4):339-52. DOI: 10.1002/pros.20131. View

Tsai H, Morais C, Alshalalfa M, Tan H, Haddad Z, Hicks J . Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res. 2015; 21(24):5619-29. PMC: 4681606. DOI: 10.1158/1078-0432.CCR-15-0744. View

Huang J, Yao J, Zhang L, Bourne P, Quinn A, di SantAgnese P . Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol. 2005; 166(6):1807-15. PMC: 1602414. DOI: 10.1016/S0002-9440(10)62490-X. View

Mirosevich J, Gao N, Gupta A, Shappell S, Jove R, Matusik R . Expression and role of Foxa proteins in prostate cancer. Prostate. 2005; 66(10):1013-28. DOI: 10.1002/pros.20299. View

Zhang Z, Rosen D, Yao J, Huang J, Liu J . Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol. 2006; 19(10):1339-43. DOI: 10.1038/modpathol.3800655. View

Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen M . Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate. 2008; 69(3):249-62. PMC: 4437562. DOI: 10.1002/pros.20877. View

10.

Yu X, Wang Y, DeGraff D, Wills M, Matusik R . Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 2010; 30(16):1868-79. PMC: 3081383. DOI: 10.1038/onc.2010.560. View

11.

Nadal R, Schweizer M, Kryvenko O, Epstein J, Eisenberger M . Small cell carcinoma of the prostate. Nat Rev Urol. 2014; 11(4):213-9. PMC: 4339095. DOI: 10.1038/nrurol.2014.21. View

12.

Khoor A, Stahlman M, Johnson J, Olson S, Whitsett J . Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors. Hum Pathol. 2004; 35(5):560-4. DOI: 10.1016/j.humpath.2004.01.017. View

13.

Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kim S . The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015; 12(6):922-36. DOI: 10.1016/j.celrep.2015.07.012. View

14.

Wang W, Epstein J . Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2007; 32(1):65-71. DOI: 10.1097/PAS.0b013e318058a96b. View

15.

Mertz K, Setlur S, Dhanasekaran S, Demichelis F, Perner S, Tomlins S . Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia. 2007; 9(3):200-6. PMC: 1838578. DOI: 10.1593/neo.07103. View

16.

Tai S, Sun Y, Squires J, Zhang H, Oh W, Liang C . PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011; 71(15):1668-79. PMC: 3426349. DOI: 10.1002/pros.21383. View

17.

Bello D, Webber M, Kleinman H, Wartinger D, Rhim J . Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis. 1997; 18(6):1215-23. DOI: 10.1093/carcin/18.6.1215. View

18.

Qi J, Nakayama K, Cardiff R, Borowsky A, Kaul K, Williams R . Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010; 18(1):23-38. PMC: 2919332. DOI: 10.1016/j.ccr.2010.05.024. View

19.

Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M . Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int. 2002; 88(9):982-3. DOI: 10.1046/j.1464-4096.2001.00936.x. View

20.

Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J . Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol. 2013; 32(5):524-36. DOI: 10.1016/j.urolonc.2013.05.011. View